Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMJEVITA vs MICARDIS HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Rheumatoid arthritis (moderate to severe active, alone or with methotrexate),Juvenile idiopathic arthritis (moderate to active polyarticular, age ≥2 years),Psoriatic arthritis (active, alone or with DMARDs),Ankylosing spondylitis (active),Crohn's disease (moderate to severe, age ≥6 years),Ulcerative colitis (moderate to severe, adults),Plaque psoriasis (moderate to severe chronic, adults),Hidradenitis suppurativa (moderate to severe, adults),Uveitis (non-infectious intermediate, posterior, and panuveitis, adults and children ≥2 years)
Treatment of hypertension, alone or in combination with other antihypertensive agents
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Adalimumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via catabolism to small peptides and amino acids.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Adalimumab is a monoclonal antibody; protein binding is negligible as it is not bound to serum proteins. However, it may bind to soluble TNF-alpha with high affinity.
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution (Vd) is approximately 4.7-6.0 L (0.06-0.08 L/kg for a 70 kg adult). This small Vd reflects distribution primarily in the vascular and interstitial spaces, consistent with a large protein.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Subcutaneous bioavailability: 64% (range 50-80%) after 40 mg SC injection. No intravenous formulation is approved; absolute bioavailability determined by comparison to IV administration.
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
No dose adjustment required for any degree of renal impairment.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
No dose adjustment required for any degree of hepatic impairment.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
For pediatric patients weighing ≥40 kg: 40 mg subcutaneously every other week; for weight <40 kg: 20 mg subcutaneously every other week.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment recommended; use with caution due to higher risk of infections.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB before and during therapy. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
None
Serious infections (bacterial, viral, fungal, including reactivation of HBV),Invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis),Malignancies (lymphoma, leukemia, melanoma, Merkel cell carcinoma, other),Anaphylaxis and allergic reactions,Demyelinating disease (new onset or exacerbation of CNS demyelinating disorders),Hematologic reactions (pancytopenia, aplastic anemia),Congestive heart failure (new onset or worsening),Lupus-like syndrome (autoantibodies, rarely clinical disease),Hepatitis B reactivation,Use with abatacept or anakinra (increased risk of infection)
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Known hypersensitivity to adalimumab or any component of the formulation,Active serious infection including sepsis
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
No specific food interactions. No dietary restrictions required.
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
Amjevita (adalimumab) is an Ig G1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and second trimesters, placental transfer is limited. Available data from the OTIS autoimmune diseases in pregnancy study and other cohort studies do not indicate a substantially increased risk of major birth defects or miscarriage with adalimumab exposure during pregnancy. However, there is a potential risk of immunosuppression in the neonate, including increased risk of infections, if the mother is exposed during the second and third trimesters. Infants should not be vaccinated with live vaccines for at least 5 months after maternal last dose.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Adalimumab is excreted in breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.04. Limited data indicate that infants are exposed to less than 1% of the maternal dose, and no adverse effects have been reported in breastfed infants. Because adalimumab is a large protein, it undergoes proteolysis in the infant's gastrointestinal tract and is not systemically absorbed. Therefore, breastfeeding is considered compatible with adalimumab therapy.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
During pregnancy, adalimumab clearance may increase, especially in the third trimester, leading to lower trough concentrations. However, no dose adjustment is routinely recommended due to lack of data showing altered clinical outcomes. Therapeutic drug monitoring is not standard, but if disease activity increases, consider modifying the dose or frequency as per non-pregnant guidelines. Postpartum, clearance returns to prepregnancy levels, so doses should be adjusted back to prepregnancy regimen if modified.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
AMJEVITA (adalimumab-atto) is a biosimilar to Humira. Administer subcutaneously; rotate injection sites. Do not administer live vaccines. Screen for TB and hepatitis B before initiation. Consider withholding for serious infections. Monitor for allergic reactions and blood dyscrasias.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
Store in refrigerator, do not freeze; protect from light.,Inject at room temperature; allow to sit out 15-30 minutes.,Rotate injection sites; avoid tender, bruised, or scarred skin.,Report signs of infection (fever, chills, cough) or allergic reaction immediately.,Do not receive live vaccines while on this medication.,Inform all healthcare providers of your use of AMJEVITA.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMJEVITA vs MICARDIS HCT, answered by our medical review team.
AMJEVITA is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.. MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMJEVITA and MICARDIS HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMJEVITA is: Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.. The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMJEVITA and MICARDIS HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMJEVITA is classified as Category C. Amjevita (adalimumab) is an IgG1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and seco. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.